Andrew R. Boll
2017
In 2017, Andrew R. Boll earned a total compensation of $524.2K as Chief Financial Officer at Imprimis Pharmaceuticals, a 50% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $45,063 |
|---|---|
| Option Awards | $104,297 |
| Salary | $285,769 |
| Other | $89,040 |
| Total | $524,169 |
Boll received $285.8K in salary, accounting for 55% of the total pay in 2017.
Boll also received $45.1K in non-equity incentive plan, $104.3K in option awards and $89K in other compensation.
Rankings
In 2017, Andrew R. Boll's compensation ranked 11,680th out of 14,666 executives tracked by ExecPay. In other words, Boll earned more than 20.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,680 out of 14,666 | 20th |
Division Manufacturing | 4,588 out of 5,772 | 21st |
Major group Chemicals And Allied Products | 1,679 out of 2,075 | 19th |
Industry group Drugs | 1,389 out of 1,731 | 20th |
Industry Pharmaceutical Preparations | 1,085 out of 1,333 | 19th |
Source: SEC filing on April 30, 2018.
Boll's colleagues
We found two more compensation records of executives who worked with Andrew R. Boll at Imprimis Pharmaceuticals in 2017.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019